Skip to main content
SpringerLink
Log in

Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist

  • Educational Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Anemia coincident with hyporesponsiveness to erythropoiesis-stimulating agents is an ongoing and prevalent problem in children with chronic kidney disease (CKD). The recently identified iron-regulatory protein hepcidin appears likely to play a significant role in this problem. Hepcidin up-regulation in the setting of CKD, with subsequent increased serum levels, results in impaired iron absorption from the intestine and decreased iron release from body storage sites. Ultimately, in the setting of such elevated levels, a state of functional iron deficiency may develop and lead to anemia due to iron-restricted erythropoiesis. Elevated hepcidin levels are expected in the face of decreased glomerular filtration rate and inflammation. Based on current evidence, it seems likely that hepcidin represents a potentially modifiable mediator of anemia of CKD and is thus a potential target for future anemia therapy. Currently, increased removal via intensified dialysis and-/or blockade of the inflammatory pathway appear to be two viable generic strategies for reducing hepcidin levels. Goals of directly manipulating the hepcidin pathway should offer the pediatric clinician new options for treating the complex anemia associated with CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316(2):73–78

    Article  PubMed  CAS  Google Scholar 

  2. Eschbach JW, Adamson JW (1999) Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int Suppl 69:S35–S43

    Article  PubMed  CAS  Google Scholar 

  3. Guyton AC, Hall JE (2000) Textbook of medical physiology, 10th edn. Saunders, Philadelphia

    Google Scholar 

  4. Geary DF, Schaefer F (2008) Comprehensive pediatric nephrology. Mosby/Elsevier, Philadelphia

    Google Scholar 

  5. Atkinson MA, Martz K, Warady BA, Neu AM (2010) Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 25(9):1699–1706

    Article  PubMed  Google Scholar 

  6. Bamgbola OF, Kaskel FJ, Coco M (2009) Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol 24(3):571–579

    Article  PubMed  Google Scholar 

  7. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Investigators TREAT (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019–2032

    Article  PubMed  Google Scholar 

  8. Unger EF, Thompson AM, Blank MJ, Temple R (2010) Erythropoiesis-stimulating agents–time for a reevaluation. N Engl J Med 362(3):189–192

    Article  PubMed  CAS  Google Scholar 

  9. Gillespie RS, Wolf FM (2004) Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatr Nephrol 19(6):662–666

    Article  PubMed  Google Scholar 

  10. National Kidney Foundation (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47(5S3):S11–S145

    Google Scholar 

  11. Handelman GJ, Levin NW (2009) Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 13(4):393–404

    Article  Google Scholar 

  12. Goodnough LT, Nemeth E, Ganz T (2010) Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116(23):4754–4761

    Article  PubMed  CAS  Google Scholar 

  13. Roy CN, Andrews NC (2005) Anemia of inflammation: the hepcidin link. Curr Opin Hematol 12(2):107–111

    Article  PubMed  CAS  Google Scholar 

  14. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 52(10):1011–1023

    Article  Google Scholar 

  15. Thomas C, Thomas L (2005) Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 1(1):14–23

    Article  Google Scholar 

  16. Malyszko J, Mysliwiec M (2007) Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 30(1):15–30

    Article  PubMed  CAS  Google Scholar 

  17. Kalantar-Zadeh K, Lee GH (2006) The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol Suppl 1:S9–S18

    Google Scholar 

  18. Babitt JL, Lin HY (2010) Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 55(4):726–741

    Article  PubMed  CAS  Google Scholar 

  19. Andrews NC (2008) Forging a field: the golden age of iron biology. Blood 112(2):219–230

    Article  PubMed  CAS  Google Scholar 

  20. Braun J, Lindner K, Schreiber M, Heidler RA, Horl WH (1997) Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 12(6):1173–1181

    Article  PubMed  CAS  Google Scholar 

  21. National Kidney Foundation (2007) KDOQI clinical practice cuideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50(3):471–530

    Article  Google Scholar 

  22. Agarwal R (2008) Iron, oxidative stress, and clinical outcomes. Pediatr Nephrol 23(8):1195–1199

    Article  PubMed  Google Scholar 

  23. Fishbane S (2008) Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines. Semin Dial 21(3):217–220

    Article  PubMed  Google Scholar 

  24. Franchini M, Montagnana M, Lippi G (2010) Hepcidin and iron metabolism: From laboratory to clinical implications. Clin Chim Acta 411(21–22):1565–1569

    Article  PubMed  CAS  Google Scholar 

  25. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB (2009) Hepcidin–a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4(6):1051–1056

    Article  PubMed  CAS  Google Scholar 

  26. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75(9):976–981

    Article  PubMed  CAS  Google Scholar 

  27. Swinkels DW, Wetzels JF (2008) Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant 23(8):2450–2453

    Article  PubMed  CAS  Google Scholar 

  28. Kemna EH, Tjalsma H, Willems HL, Swinkels DW (2008) Hepcidin: from discovery to differential diagnosis. Haematologica 93(1):90–97

    Article  PubMed  CAS  Google Scholar 

  29. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M (2008) Immunoassay for human serum hepcidin. Blood 112(10):4292–4297

    Article  PubMed  CAS  Google Scholar 

  30. Nemeth E (2010) Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol. doi:10.1155/2010/750643

    Google Scholar 

  31. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC (2007) Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 109(9):4038–4044

    Article  PubMed  CAS  Google Scholar 

  32. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M (2006) Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am J Hematol 81(11):832–837

    Article  PubMed  CAS  Google Scholar 

  33. Malyszko J, Malyszko JS, Kozminski P, Mysliwiec M (2009) Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin. Ren Fail 31(10):876–883

    Article  PubMed  CAS  Google Scholar 

  34. Means RT (2004) Hepcidin and cytokines in anaemia. Hematology 9(5–6):357–362

    Article  PubMed  CAS  Google Scholar 

  35. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113(9):1271–1276

    PubMed  CAS  Google Scholar 

  36. Balakrishnan VS, Guo D, Rao M, Jaber BL, Tighiouart H, Freeman RL, Huang C, King AJ, Pereira BJ, HEMO Study Group (2004) Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int 65(4):1449–1460

    Article  PubMed  CAS  Google Scholar 

  37. Poole S, Bird TA, Selkirk S, Gaines-Das RE, Choudry Y, Stephenson SL, Kenny AJ, Saklatvaa J (1990) Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 2(6):416–422

    Article  PubMed  CAS  Google Scholar 

  38. Bemelmans MH, Gouma DJ, Buurman WA (1993) Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 150(5):2007–2017

    PubMed  CAS  Google Scholar 

  39. Zwolinska D, Medynska A, Szprynger K, Szczepanska M (2000) Serum concentration of IL-2, IL-6, TNF-alpha and their soluble receptors in children on maintenance hemodialysis. Nephron 86(4):441–446

    Article  PubMed  CAS  Google Scholar 

  40. Goldstein SL, Leung JC, Silverstein DM (2006) Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. Clin J Am Soc Nephrol 1(5):979–986

    Article  PubMed  CAS  Google Scholar 

  41. Pecoits-Filho R, Sylvestre LC, Stenvinkel P (2005) Chronic kidney disease and inflammation in pediatric patients: from bench to playground. Pediatr Nephrol 20(6):714–720

    Article  PubMed  Google Scholar 

  42. Sylvestre LC, Fonseca KP, Stinghen AE, Pereira AM, Meneses RP, Pecoits-Filho R (2007) The malnutrition and inflammation axis in pediatric patients with chronic kidney disease. Pediatr Nephrol 22(6):864–873

    Article  PubMed  Google Scholar 

  43. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J (2004) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65(3):1009–1016

    Article  PubMed  Google Scholar 

  44. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD (2003) Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42(4):761–773

    Article  PubMed  Google Scholar 

  45. Young B, Zaritsky J (2009) Hepcidin for clinicians. Clin J Am Soc Nephrol 4(8):1384–1387

    Article  PubMed  CAS  Google Scholar 

  46. Tessitore N, Girelli D, Campostrini N, Bedogna V, Pietro Solero G, Castagna A, Melilli E, Mantovani W, De Matteis G, Olivieri O, Poli A, Lupo A (2010) Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 25(12):3996–4002

    Article  PubMed  CAS  Google Scholar 

  47. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, Kobold U, Mayer G (2009) Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 39(10):883–890

    Article  PubMed  CAS  Google Scholar 

  48. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB (2010) Reduction of Serum Hepcidin by Hemodialysis in Pediatric and Adult Patients. Clin J Am Soc Nephrol 5(6):1010–1014

    Article  PubMed  Google Scholar 

  49. Ganz T, Nemeth E (2009) Iron sequestration and anemia of inflammation. Semin Hematol 46(4):387–393

    Article  PubMed  CAS  Google Scholar 

  50. Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T (2007) Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 92(6):857–858

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors thank Dr. Cindy Roy for valuable assistance in designing the figures.

Author information

Authors and Affiliations

  1. Division of Pediatric Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Meredith A. Atkinson

  2. Division of Nephrology, BC Children’s Hospital, University of British Columbia, Vancouver, BC, Canada

    Colin T. White

Authors
  1. Meredith A. Atkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Colin T. White
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meredith A. Atkinson.

Additional information

Answers:

1. d. All of the above

2. c. Tissue hypoxia

3. a. Macrophages and enterocytes

4. d. All of the above

5. b. Dialysis

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atkinson, M.A., White, C.T. Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pediatr Nephrol 27, 33–40 (2012). https://doi.org/10.1007/s00467-011-1832-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-011-1832-y

Keywords

Search

Navigation